EOLS Stock Cash Flow Statements

Evolus Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Evolus Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31

cash flows from operating activities
net income	-17,142,000	-18,892,000	-6,791,000	-19,170,000	-11,350,000	-13,109,000	-11,831,000	-16,923,000	-18,140,000	-14,791,000	-13,164,000	-20,276,000	-23,471,000	-17,501,000	-18,177,000	-19,433,000	-15,601,000	6,401,000	-110,694,000	-11,459,000	-21,125,000	-19,735,000	-14,508,000	-26,984,000	-37,567,000	-10,975,000	-12,442,000	-11,830,000	-16,433,000	-6,162,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	1,738,000	1,563,000	1,374,000	1,087,000	1,427,000	1,409,000	1,373,000	1,311,000	1,247,000	1,202,000	1,027,000	920,000	853,000	922,000	920,000	923,000	1,746,000	2,033,000	1,876,000	1,744,000	1,658,000	1,749,000	1,468,000	1,202,000	978,000	484,000	2,000	3,000
stock-based compensation	4,488,000	5,928,000	6,171,000	5,220,000	5,784,000	5,079,000	4,397,000	4,596,000	4,171,000	3,294,000	2,412,000	2,483,000	2,979,000	2,959,000	2,649,000	2,476,000	2,861,000	1,590,000	2,630,000	2,952,000	2,374,000	2,628,000	2,537,000	2,526,000	2,457,000	1,998,000	1,860,000	1,481,000	2,624,000	1,006,000
benefit from bad debts	703,000	1,051,000	790,000	889,000	582,000	188,000	86,000	1,012,000	69,000	273,000	235,000	624,000	274,000	465,000	88,000	188,000	-297,000	610,000	-373,000	-168,000	0	2,607,000
amortization of operating lease right-of-use assets	309,000	263,000	238,000	184,000	153,000	148,000	144,000	166,000	215,000	209,000	202,000	197,000	191,000	185,000	180,000	176,000	170,000	166,000	164,000	160,000	161,000	169,000	171,000	179,000	304,000	219,000
amortization of debt discount and issuance costs	309,000	301,000	298,000	290,000	282,000	277,000	273,000	266,000	279,000	298,000	281,000	272,000	270,000	263,000	59,000	302,000	294,000	286,000	698,000	703,000	643,000	647,000	643,000	624,000	608,000	281,000
deferred income taxes	20,000	-5,000	-23,000	0	-3,000	5,000					-3,000	-4,000	6,000	-17,000					-154,000	-11,000	-66,000	256,000	-156,000	-149,000	-227,000	-14,523,000
revaluation of contingent royalty obligation payable to evolus founders	-3,914,000	2,151,000		2,428,000	1,605,000	1,578,000		1,802,000	1,682,000	1,648,000		1,216,000	1,414,000	1,316,000		1,400,000	1,381,000	1,268,000		-2,471,000	2,433,000	-9,884,000		1,795,000
other adjustments to operating activities
changes in operating assets and liabilities:
inventories	-8,341,000	4,050,000	979,000	-1,476,000	-1,560,000	5,309,000	4,847,000	4,956,000	848,000	-6,458,000	4,595,000	-2,658,000	-7,054,000	-5,571,000	4,182,000	-7,181,000	-3,129,000	3,149,000	3,006,000	1,266,000	2,199,000	-1,929,000	1,743,000	5,297,000	-8,944,000	-2,578,000
accounts receivable	-958,000	-823,000	-3,829,000	-2,383,000	-9,491,000	-3,899,000	-151,000	-2,480,000	-5,610,000	-1,280,000	-1,763,000	-518,000	-4,500,000	-2,608,000	-1,456,000	-1,613,000	-3,751,000	1,254,000	2,092,000	-2,582,000	1,757,000	-2,352,000	-3,842,000	-5,796,000
prepaid expenses	-1,340,000	-103,000	50,000	2,108,000	171,000	22,000	-2,045,000	642,000	-138,000	-257,000	-246,000	3,750,000	-2,873,000	549,000		1,253,000	-273,000	-636,000
accounts payable	-777,000	4,722,000	-2,889,000	3,526,000	-1,155,000	909,000	-5,806,000	1,364,000	283,000	3,142,000	-1,370,000	-2,056,000	2,923,000	1,471,000	1,525,000	-763,000	259,000	-1,808,000	5,165,000			332,000	-553,000			305,000	897,000	-93,000	266,000	205,000
accrued expenses	1,337,000	-14,172,000	5,877,000	2,160,000	7,851,000	-8,874,000	7,100,000	2,529,000	2,075,000	-2,685,000	-5,089,000	1,346,000	7,398,000	-8,854,000	6,557,000	-922,000	11,791,000	3,465,000	2,678,000			-3,949,000	-4,742,000			2,667,000	-1,092,000	1,890,000	574,000	1,361,000
operating lease liabilities	-177,000	-79,000	-194,000	-169,000	-182,000	-171,000	-159,000	-198,000	-280,000	-270,000	-254,000	-248,000	-243,000	-232,000	-219,000	-213,000	-209,000	-197,000	-178,000	-174,000	-201,000	-181,000	-123,000	-122,000	-187,000	-222,000
other operating assets
net cash from operating activities	-24,791,000	-15,632,000	4,808,000	-5,722,000	-6,470,000	-10,615,000	813,000	-924,000	-13,310,000	-20,587,000	-8,774,000	-17,051,000	-20,888,000	-38,199,000	-9,044,000	-32,125,000	16,116,000	-8,335,000	-2,266,000	-13,713,000	-13,945,000	-27,947,000	-15,922,000	-25,103,000	-33,158,000	-19,200,000	-12,006,000	-5,797,000	-5,663,000	-2,201,000
capex	-688,000	-319,000	-438,000	-313,000	-465,000	-256,000	-209,000	-29,000	-8,000	-227,000	-866,000	-509,000	-231,000	-12,000	0	0	0	0	-17,000	-121,000	-112,000	-565,000	1,000	0	0	0	0	0	0	0
free cash flows	-25,479,000	-15,951,000	4,370,000	-6,035,000	-6,935,000	-10,871,000	604,000	-953,000	-13,318,000	-20,814,000	-9,640,000	-17,560,000	-21,119,000	-38,211,000	-9,044,000	-32,125,000	16,116,000	-8,335,000	-2,283,000	-13,834,000	-14,057,000	-28,512,000	-15,921,000	-25,103,000	-33,158,000	-19,200,000	-12,006,000	-5,797,000	-5,663,000	-2,201,000
cash flows from investing activities
purchases of property and equipment	-688,000	-319,000	-438,000	-313,000	-465,000	-256,000	-209,000	-29,000	-8,000	-227,000	-866,000	-509,000	-231,000	-12,000					-17,000	-121,000	-112,000	-565,000	1,000	0			0	0
additions to capitalized software	-1,579,000	-1,542,000	-924,000	-1,097,000	-789,000	-541,000	-152,000	-510,000	-208,000	-284,000	-525,000	-390,000	-157,000	-249,000	3,000	21,000	-386,000	-215,000	-282,000	-578,000	-528,000	-935,000	-1,142,000	-639,000	-1,618,000	-823,000
net cash from investing activities	-2,267,000	-1,861,000	-1,362,000	-1,410,000	-1,254,000	-797,000	-361,000	-539,000	-216,000	-511,000	-1,391,000	-899,000	-388,000	-261,000	-390,000	21,000	-386,000	4,785,000	19,701,000	29,301,000	9,380,000	-46,188,000	13,974,000	34,390,000	8,227,000	-80,025,000	0	0
cash flows from financing activities
payment of contingent royalty obligation to evolus founders	-2,051,000	-2,365,000	-1,829,000	-2,005,000	-1,778,000	-1,829,000	-1,499,000	-1,479,000	-1,251,000	-1,308,000	-1,016,000	-1,114,000	-1,016,000	-1,039,000	-802,000	-783,000	-983,000	-529,000	0	-233,000	-315,000	-583,000	-395,000	-69,000
proceeds from issuance and modification of debt instruments
payments for debt modification fees and costs
proceeds from follow-on offering
payments for offering costs			0	0											0	0											0	-300,000	-74,000	-686,000
issuance of common stock in connection with incentive equity plan	323,000	742,000		589,000	2,300,000	487,000	29,000	60,000	109,000	26,000	0	355,000	167,000	17,000	1,000	-1,000	644,000	11,000					1,346,000	314,000
payment of financing lease obligation
net cash from financing activities	20,663,000	-1,631,000	-1,313,000	-1,416,000	4,481,000	45,662,000	23,522,000	-1,419,000	23,820,000	-1,282,000	-1,516,000	-759,000	-849,000	-1,022,000	47,894,000	8,163,000	93,836,000	-76,841,000	0	39,767,000	-315,000	-1,105,000	72,724,000	-460,000	853,000	60,430,000	0	67,380,000	-313,000	51,771,000
effect of exchange rates on cash and cash equivalents
net increase in cash and cash equivalents
cash and cash equivalents, beginning of period	0	86,952,000	0	0	0	62,838,000	0	0	0	53,922,000	0	0	0	146,256,000	0	0	0	102,562,000	0	0	0	109,892,000	0	0	0	93,162,000
cash and cash equivalents, end of period	-6,156,000	67,894,000	1,917,000	-8,636,000	-3,287,000	96,958,000	24,153,000	-3,020,000	10,242,000	31,463,000	-11,650,000	-18,912,000	-22,187,000	106,671,000	38,460,000	-23,941,000	109,566,000	22,171,000	17,435,000	55,355,000	-4,880,000	34,652,000	70,776,000	8,827,000	-24,078,000	54,367,000
other		146,000
changes in assets and liabilities:
other assets		-1,733,000	1,192,000	-416,000	-584,000	514,000	-974,000	33,000	-11,000	88,000		-2,099,000	945,000	3,454,000			-4,626,000	-1,657,000	201,000	1,105,000	98,000	93,000
proceeds from follow-on offering, net of underwriters fees				0	4,207,000	47,004,000										0
tax withholding paid on behalf of employees for stock-based awards		-8,000																								-58,000
effect of exchange rates on cash		66,000		-88,000	-44,000	-130,000	179,000	-138,000	-52,000	-79,000	31,000	-203,000	-62,000	-103,000
change in cash and cash equivalents		-19,058,000	1,917,000	-8,636,000	-3,287,000	34,120,000	24,153,000	-3,020,000	10,242,000	-22,459,000	-11,650,000	-18,912,000	-22,187,000	-39,585,000	38,460,000	-23,941,000	109,566,000	-80,391,000	17,435,000	55,355,000	-4,880,000	-75,240,000	70,776,000	8,827,000	-24,078,000	-38,795,000
revaluation of contingent royalty obligation to evolus founders
non-cash in-process research and development expense
accrued litigation settlement							0	0	0	-5,000,000	0	0	0	-15,000,000	0
proceeds from issuance of long-term debt, net of discounts							25,000,000	0															0	0	0	73,906,000
payments for debt issuance costs							-8,000	0															0	0	0	-2,205,000
proceeds from follow-on offering, net of underwriting fees
cash proceeds from exercise of stock options
tax withholding paid on behalf of employees for net share settlement
amortization of discount on short-term investments																			-7,000	-30,000	-221,000	-169,000			-466,000	-120,000
income from extinguishment of debts															0	0	0	968,000
other current assets
maturities of short-term investments															0	0	0	5,000,000	20,000,000	30,000,000	35,000,000	5,000,000	30,000,000	40,000,000
repayment of long term debt															0	0	0	-76,323,000
repayment of promissory note payable to evolus founders
proceeds from atm sales of shares															0	8,947,000
paid-in-kind interest on convertible note																-1,000	0	273,000	303,000
consideration receivable from daewoong																		-25,500,000
non-cash portion of accrued settlement expenses
prepaid expenses and other current assets																			-1,009,000	-1,755,000	-697,000	1,771,000	-468,000	591,000	-348,000	-1,649,000	-253,000	115,000	-498,000	-356,000
purchases of short-term investments																			0	0	-24,980,000	-49,688,000	-14,885,000	-4,971,000	-14,809,000	-79,202,000
proceeds from issuance of convertible note																			0
payment for debt obligation																			0	0	0	-522,000	-339,000
accrued settlement expenses
milestone payment for intangible assets																							-1,000,000	0	0	-2,000,000
proceeds from issuance of term loan, net of discounts
accounts payable and accrued expenses
provisions for rebate and coupon programs																							5,654,000
deferred rent																											-5,000	-3,000	-3,000	-2,000
proceeds from initial public offering, net of underwriting fees
related party borrowings																											0	0	0	1,127,000
payments on related party borrowings																											0	0	0	-5,000,000
accretion of discount on short-term investments
proceeds from initial public offering, net of underwriters fees																												0	0	56,330,000
revaluation of contingent royalty obligation payable to evolus founders, a related party																										4,913,000		2,300,000
related party accounts payable																														730,000
payment of contingent royalty obligation to evolus founders, a related party																										-9,213,000
interest expense																											114,000	321,000	321,000	107,000
tax benefit from therapeutic option right
revaluation of contingent royalty obligation to evolus founders, a related party
change in cash and restricted cash																											-12,006,000	61,583,000
cash and restricted cash, beginning of period
cash, end of period																											-12,006,000	61,583,000
supplemental disclosure of cash flow information
noncash financing activities:
related party receivable																											0	0	0	73,690,000
note obligation																											0	0	0	-140,688,000
contingent royalty obligation payable to evolus founders, a related party																											0	0
contingent promissory note payable to evolus founders, a related party																											0	0
capital contribution from parent, convertible note write-off																											0	0	0	66,998,000
capital distribution to parent
capital contribution from parent, forgiveness of related party borrowings																											0	0	0	13,188,000
capital contribution from parent - therapeutic option right, net of tax
deferred offering costs accrued, unpaid
deferred offering costs																											0
accounts payable, paid by parent																											0	0	0	-163,000
•
income tax expense																												19,000	12,000	10,000
minimum tax withholding paid on behalf of employees for share-based awards																												0
cash and restricted cash, beginning
non-cash financing activities:
capital distribution from parent
deferred ipo costs																													0	-2,885,000
deferred offering costs, unpaid																													52,000	-74,000
revaluation of contingent royalty obligation payable to related party																														900,000
change in cash, cash equivalents, and restricted cash																														49,570,000
cash, cash equivalents, and restricted cash, beginning
cash and cash equivalents, ending																														49,570,000
contingent royalty obligation payable to related party																														39,700,000
contingent promissory note payable to related party																														16,042,000
adjustments to reconcile net income to net cash from operating activities
changes in assets and liabilities
release (payment) of restricted cash
deemed distribution
capital contribution - therapeutic option right, net of tax

We provide you with 20 years of cash flow statements for Evolus stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Evolus stock. Explore the full financial landscape of Evolus stock with our expertly curated income statements.

The information provided in this report about Evolus stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.